Sun Pharmaceutical Industries Ltd News
Analyst suggests 'Bull Spread' on Midcap Nifty, Sun Pharma; check strategy
Nandish Shah of HDFC Securities has shared Bull Spread' on strategy on Midcap Nifty and Sun Pharma
 "Analyst suggests 'Bull Spread' on Midcap Nifty, Sun Pharma; check strategy")
Sun Pharma exploring Eurobonds, bond swaps to fund US-based Organon buy
According to bankers, the Indian pharma major plans to raise around $10 billion from various sources, while the remaining will be funded through internal accruals
 "Sun Pharma exploring Eurobonds, bond swaps to fund US-based Organon buy")
Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?
Supported by the Sun Pharma's proven record of strong cash flows, analysts remain confident in gradual deleveraging over time.
 "Sun Pharma up 12% in 4 days, nears 52-week high; analysts see more upside?")
Sun Pharma bets on Organon front-end to drive global growth, efficiencies
Sun Pharma sees its Organon acquisition as a platform to expand globally, boost in-licensing, and improve long-term efficiencies through a stronger commercial front-end
Nifty Apr F&O rollovers hint at cautious stance; ONGC among stocks in focus
The Nifty rollovers to May were below average, suggesting a likely cautious stance among participants and slight hesitation to carry forward aggressive bets, says Axis Securities.
 "Nifty Apr F&O rollovers hint at cautious stance; ONGC among stocks in focus")
Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal
Combined entity to have revenue of $12.4 billion; enters biosimilars big league
 "Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal")
Lack of growth visibility at Organon could cap Sun Pharma's gains
Sun Pharma's Organon deal lifts stock, but growth concerns and high debt at the acquired firm may cap upside despite synergy potential
 "Lack of growth visibility at Organon could cap Sun Pharma's gains")
Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details
Among others, Sun Pharma was the top gainer up over 7 per cent, followed by Gland Pharma, Alkem Laboratories, Zydus Lifesciences and Wockhardt up over 2 per cent
 "Sun Pharma, Dr Reddy's Labs, Onesource: Nifty Pharma rallies 3%; details")
Sun Pharma rallies 6%, top gainer among Sensex stocks; here's why
Sun Pharma to acquire all outstanding shares of Organon for $14.00 per share in an all cash transaction with an enterprise valuation of $11.75 billion.
Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal
April 26 (Reuters) - India's Sun Pharmaceutical Industries will uy Organon & Co in an all-cash deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.
Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%
Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.
 "Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%")
Pharma cos brace for soft Q4; US drag persists; domestic growth cushions
Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements
 "Pharma cos brace for soft Q4; US drag persists; domestic growth cushions")
Sun Pharma stock falls 5% in strong market: What's worrying investors?
Sun Pharma shares fall 5 per cent amid Organon deal buzz and US tariff concerns. Tech charts show the stock has a 'bearish' outlook
Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?
Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.
 "Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?")
Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount
Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country
Astral, Glenmark, Nalco among high conviction F&O bets in April: Systematix
The futures & options market positioning reflects heavy short build-up, creating conditions for sharp but temporary short-covering rallies, says Systematix Institutional Equities.
 "Astral, Glenmark, Nalco among high conviction F&O bets in April: Systematix")
10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt
Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations
 "10 pharma firms launch semaglutide in India; Nomura sees ₹12k-cr mkt")
Stocks to Watch today, March 17: RIL, Tata Motors, Sun Pharma, RVNL, GMDC
Stocks to Watch today, March 17: Reliance Industries, Tata Motors, Sun Pharma, RVNL, GMDC, RailTel, and Sagar Cements are among the top stocks to watch today
 "Stocks to Watch today, March 17: RIL, Tata Motors, Sun Pharma, RVNL, GMDC")
Nifty Pharma index hits 52-week high; Ipca, Aurobindo rally up to 4%
In the past one month, the Nifty Pharma index has rallied 4.5 per cent, as against 7.8 per cent decline in the benchmark Nifty 50.
Sun Pharma up 5% in 1 week, nears 52-week high; what's driving this stock?
Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.